Form 4: Redmile Group Adjusts ADC Therapeutics Stake

Redmile Group, LLC reports significant transactions involving ADC Therapeutics SA common stock, reflecting strategic adjustments in beneficial ownership.

Summary

• Redmile Group, LLC, a significant holder and director of ADC Therapeutics SA, has reported a series of transactions involving the company's common stock.
• These transactions occurred between March 31, 2026, and April 2, 2026.
• The filings detail the acquisition and disposition of common stock, with reported prices ranging from $3.25 to $3.83.
• Redmile Group, LLC, along with RedCo II Master Fund, L.P. and Jeremy Green, are listed as reporting persons, with beneficial ownership attributed to Redmile as the investment manager and Jeremy Green as the principal.
• The reporting persons disclaim beneficial ownership beyond their pecuniary interest.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports routine trading activity by a significant stakeholder and includes disclaimers that limit definitive interpretation of conviction.

Positives

• Redmile Group, LLC, a key stakeholder, continues to actively manage its position in ADC Therapeutics SA, indicating ongoing strategic engagement.
• The transactions involve a range of prices, suggesting flexibility in execution and potentially opportunistic adjustments to the portfolio.

Negatives

• The filing indicates sales were made at prices lower than previous purchases, though the reporting persons state no profits were earned under Section 16(b) liability.
• The nature of the transactions, involving both acquisitions and dispositions, could imply a rebalancing of the investment rather than a strong conviction play.

Risks

• The filing does not explicitly detail future risks, but the active trading by a significant stakeholder could indicate market uncertainty or strategic shifts within Redmile Group's investment strategy.
• The disclaimer of beneficial ownership beyond pecuniary interest may suggest a complex ownership structure or a desire to limit liability, which could be a point of scrutiny.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance from ADC Therapeutics SA. The transactions reported are from Redmile Group, LLC, reflecting their investment strategy and adjustments.

Management Comments

• "The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose."
• "The sales reported herein were effected within a period of less than six months from the purchases of pre-funded warrants to purchase the Issuers' Common Stock reported in the Form 4 filed by the Reporting Persons on October 28, 2025. However, the sales reported herein were effected at a price lower than the previous purchases that were reported in the Form 4 filed on October 28, 2025, such that no profits have been earned by the Reporting Persons, and so the Reporting Persons have no additional liability under Section 16(b)."

Industry Context

StockSavvy.ai notes that Form 4 filings by significant holders like Redmile Group often signal shifts in institutional sentiment or strategic portfolio adjustments within the biotechnology sector, which is characterized by high volatility and R&D-driven news.

Stakeholder Impact

• Shareholders may interpret Redmile Group's trading activity as a signal of their confidence or rebalancing strategy, potentially influencing market perception.
• Creditors and other financial stakeholders may note the active management of a significant stake, which could indirectly reflect on the company's perceived stability or future prospects.

Next Steps

• Continued monitoring of Redmile Group's trading activity in ADC Therapeutics SA for further insights into their investment strategy.
• Review of future SEC filings by ADC Therapeutics SA for operational and financial updates.

Key Dates

Keywords

ADC Therapeutics SA, ADCT, Redmile Group, Form 4, Beneficial Ownership, Common Stock, Securities Trading, SEC Filing, Investment Management